TNF and rheumatoid arthritis: ADL, a fully human monoclonal antibody that targets TNF, has demonstrated safety and efficacy across a range of IDRs including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) [1–3].